GRAIL Inc. (GRAL)
NASDAQ: GRALHealth CareMedical SpecialitiesUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
GRAL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $5.94B
- EPS (TTM)
- -$9.39
- Dividend yield
- None
- 52-week range
- 41.50 – 166.48
- Day range
- 130.62 – 139.00
- Volume / Avg
- 991.09K / 930.77K
- Beta
- —
- Shares outstanding
- 44.67M
52-week range
GRAL stock today
On Oct 7, GRAL ended the session at $132.90, shedding $4.38 (3.19%), versus the S&P 500's 0.22% decline. At this level, GRAL sits in the middle of its 52-week range of $41.50 to $166.48: 20.2% below the high, set on Oct 6, 2026 and 220.2% above the low. GRAL is up 55.3% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 111.6%.
GRAIL has posted a net loss over the last twelve months (EPS of -$9.39), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About GRAIL
Company profileGRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development.
- Sector
- Health Care
- Industry
- Medical Specialities
- CEO
- Dr. Joshua J. Ofman M.D., M.S.H.S
- Headquarters
- Menlo Park, CA
- Employees
- 910
- Website
- grail.com
Financial highlights
Full financialsIn fiscal 2025, GRAIL generated $147.2 million in revenue, up 17.2% from fiscal 2024, its 3rd consecutive year of revenue growth. GRAIL reported a net loss of $408.4 million, compared with a loss of $2.03 billion a year earlier. Operating margin was -382.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2023 |
|---|---|---|---|---|
| Revenue | $147.17M | $125.59M | $93.11M | $55.55M |
| Growth | +17.18% | +34.90% | +67.61% | — |
| Net income | $-408.35M | $-2.03B | $-1.47B | $-5.40B |
| EPS (diluted) | $-11.11 | $-63.54 | $-47.21 | $-173.89 |
Analyst forecast
ForecastConsensus (11 analysts)
buy
Avg. price target
$112.40-15.43%
- Strong buy 0
- Buy 5
- Hold 6
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Q2 2026)
- Aug 6, 2026
- EPS actual vs est.
- $-2.56 vs —
GRAIL peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RDNTRadNet Inc. | 68.61 | -2.38% | $5.40B | vs GRAL |
| CONConcentra Group Holdings Parent Inc. | 36.40 | 0.00% | $4.64B | vs GRAL |
| BLLNBillionToOne Inc. Class A | 95.75 | -4.19% | $4.52B | vs GRAL |
| CAICaris Life Sciences Inc. | 27.10 | -1.29% | $7.66B | vs GRAL |
| VCYTVeracyte Inc. | 43.16 | -3.34% | $3.47B | vs GRAL |
| CDNACareDx Inc. | 63.04 | -1.18% | $3.26B | vs GRAL |
| CELCCelcuity Inc. | 65.78 | -7.68% | $3.22B | vs GRAL |
| ACHCAcadia Healthcare Company Inc. | 29.23 | +0.65% | $2.72B | vs GRAL |
Indexes, lists and sector
GRAIL stock FAQ
What is GRAIL's stock price today?
GRAL last traded at $132.90 as of Oct 7, 4:00 PM EDT, down 3.19% on the day. Prices are delayed at least 15 minutes.
Who is GRAIL's CEO?
Dr. Joshua J. Ofman M.D., M.S.H.S is the chief executive officer of GRAIL Inc., which has about 910 employees.
What is the GRAL 52-week high?
The 52-week high for GRAL is $166.48 and the 52-week low is $41.50. The stock is currently 20.2% below its high.